Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA6 | P23280 | 4/20 | 0.47 |
| ▸ | CA7 | P43166 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA4 | P22748 | 3/20 | 0.47 |
| ▸ | CA5A | P35218 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.47 |
| ▸ | DVL1 | O14640 | 3/20 | 0.47 |
| ▸ | DVL3 | Q92997 | 3/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041117 | 0.67 | ALDH1A1 (0.69) | SGMS2KMT2AALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL9812825 | 0.66 | NPC1 (0.54) | CA12CA2CA6CA7CA9 | |
| SCHEMBL4229605 | 0.66 | NPC1 (0.65) | KMT2AALDH1A1RAB9AMEN1HPGD | |
| SCHEMBL11236668 | 0.66 | RAB9A (0.71) | SGMS2KMT2AALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL15942792 | 0.66 | MEN1 (0.57) | CNR1CNR2SGMS2KMT2AALDH1A1 | |
| SCHEMBL30876857 | 0.65 | NPC1 (0.66) | CA12CA2CA6CA7CA9 | |
| SCHEMBL874583 | 0.65 | NPC1 (0.66) | CA12CA2CA6CA7CA9 | |
| SCHEMBL13978402 | 0.64 | NPC1 (0.62) | CA12CA2CA6CA7CA9 | |
| SCHEMBL31670543 | 0.64 | CA12 (1.00) | CA12CA2CA6CA7CA9 | |
| SCHEMBL18425872 | 0.64 | CA12 (1.00) | CA12CA2CA6CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376229-B2 | Method of treating or preventing neurodegeneration | REPRISE PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376229-B2 | Method of treating or preventing neurodegeneration | TRPM4, TRPM5, TRPM2 | CNR1 829/4885CNR2 493/4885CA12 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.